The dividend yield is computed based on the closing price of 29th August 2024. We have considered companies that have consistently paid dividend in the last 3 years – i.e FY24/CY23, FY23/CY22 and FY22/CY21. The * mark indicates data for FY23/CY22.
MCX is scaling new heights; improving visibility. Buy for target price of ₹6000 (23% upside): HDFC Sec
We recently met with MCX management. We gained more confidence in their strategic direction, which includes (1) launching new products such as monthly series and index options, (2) continuously enhancing the technology stack, and (3) focusing on increasing institutional participation and hedging activity on the platform
Archean Chemical Industries is a net cash company with strong entry barriers having strong relationship with its customers. Buy for target price of ₹1158 (50% upside): SMIFS
Archean Chemical Industries Ltd (ACIL) is the leading player in marine speciality chemicals manufacturing & exporting bromine, industrial Salts & SOP to its global customers. The company’s competitive edge in the global market is because of its low cost & high efficiency processes, making it unique & standout player amongst its competitors.
SENCO is one of the most promising players in the organized retail jewelry market. Buy for target price of ₹1350 (23% upside): Motilal Oswal
SENCO is one of the most promising players in the organized retail jewelry market. The company has a pan-India presence with a strong network in the east region (store/revenue mix of 75%/ 80%). SENCO operated a total of 165 stores across India, with 97 company-owned stores and 68 franchise stores as of Jun’24. SENCO holds ~4% market share in the eastern region, predominately in West Bengal, where 75% of its eastern region stores are located.
NIFTY target increased to 26820 + 18 High Conviction Model Portfolio of Large & Mid-Cap stocks by PL
Model Portfolio: We are cutting weights on ICICI, KMB, Maruti, ABB, L&T, HDFC AMC and ITC. We are increasing weights on M&M, Ambuja Cement, Ultratech, Interglobe Aviation, Britannia Inds and LTI Mindtree. We are adding Indusind Bank in model portfolio while we remove Apollo Hospitals. We are increasing weights in Consumer, Cement, IT and Banks while cut weights in Capital Goods, Healthcare and AMC
Mphasis is taking giant strides to capture the early-mover advantage in Gen-AI domain. Buy for target price of ₹3500 (17% upside): Nuvama
Mphasis has rallied 25% in the last three months, fuelled by expectations of interest rate cuts in US and early signs of a recovery in US-BFS. We see Mphasis at an inflection point – where the factors that led to its underperformance over the last two years – are now likely to reverse, leading to outperformance. We are upgrading FY25E/26E EPS by 2%/4% and target valuation to 30x Sep-26 PE (from 27x) – on better growth visibility; upgrade to ‘BUY’ with a target price of INR3,500
Awfis Space Solutions is seeing favorable market dynamics, flex seat demand to grow at 23.3% CAGR over 2023-26E. Buy for target price of ₹1013 (35% upside): Nuvama
Favorable market dynamics, flex seat demand to grow at 23.3% CAGR over 2023-26E, led by i. Sharp increase in the number of start-ups ii. Influx of GCCs given the strong, diverse and relatively low-cost talent pool iii. Rising need for a flexible workspace on hybrid mode of working, ‘return to office’, decentralization iv. Mutual commercial benefits of flex workspaces for both, owner and tenant v. Supply to lag demand growth, inventory set to grow at 16.6% CAGR over 2023-26E
Pharma is back on the growth track with robust revenue, higher profitability & cost optimization. Top 3 Pharma stocks to buy by Axis Securities
In Q1FY25, the Pharma Coverage universe posted robust revenue growth of 11%/4% YoY/QoQ, driven by a strong domestic market, new launches (especially Darunavir, DDR D, gMyrbetriq, and gSpiriva), lower price erosion, gross margin expansion through cost optimization, and growth in the US base business portfolio. EBITDA margin improved by a healthy ~250bps/120bps YoY/QoQ amidst normalizing cost inflation and stabilizing prices.
Aditya Birla Capital Ltd is a financial conglomerate well poised for accelerated growth!!! Buy for target price of ₹280 (26.2% upside): SBI Securities
Aditya Birla Capital Limited (ABCL) is a diversified financial services group that operates in various businesses including non-banking finance, housing finance, life insurance, standalone health insurance, asset management, stock and securities broking, wealth services and asset reconstruction. ABCL has envisioned the ‘One ABC One P&L’ approach, which focuses on a business strategy that revolves around the three levers i.e One Customer, One Experience and One Team. ABCL has been prioritizing creating seamless, technology-driven loan processes by utilizing its group-level ecosystem
Nifty 12 month target using FY25E EPS & PE of 22x is 27,500. Use dips to build a long-term portfolio of quality stocks: ICICI Direct
Incorporating revised earnings, our estimates don’t undergo any major change. We value Nifty at 27,500 i.e. 22x PE on FY26E, offering healthy 12% potential upside. This is our 12 months rolling target. We are upgrading our PE valuation multiples to 22x vs. 20x earlier amid greater macro-economic stability, firm political mandate, thrust on policy continuity & further attractiveness of equity as an investment class vs. peers. Decline in interest rates will be further positive.
Recent Comments